Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Aridis Pharmaceuticals (ARDS) had Consolidated Net Income/Loss of $-30.37M for the most recently reported fiscal year, ending 2022-12-31.
| Income Statement Financials | |
$3.09M |
|
$-30.37M |
|
-- |
|
$3.09M |
|
$33.08M |
|
$-29.99M |
|
$-0.38M |
|
$-30.37M |
|
$-30.37M |
|
$-30.37M |
|
$-30.37M |
|
|
Consolidated Net Income/Loss |
$-30.37M |
$-30.37M |
|
$-29.99M |
|
$-29.51M |
|
18.78M |
|
18.78M |
|
$-1.62 |
|
$-1.62 |
|
| Balance Sheet Financials | |
$11.63M |
|
$0.73M |
|
$3.07M |
|
$14.70M |
|
$36.90M |
|
-- |
|
$2.03M |
|
$38.93M |
|
$-24.23M |
|
$-24.25M |
|
$-24.23M |
|
27.03M |
|
| Cash Flow Statement Financials | |
$-29.13M |
|
$-0.08M |
|
$14.78M |
|
$19.99M |
|
$5.56M |
|
$-14.43M |
|
$1.48M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.32 |
|
-- |
|
-- |
|
-- |
|
-0.18 |
|
100.00% |
|
-970.33% |
|
-970.33% |
|
-954.58% |
|
-982.56% |
|
-982.56% |
|
$-29.21M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
-- |
|
2.49 |
|
146.43 |
|
125.33% |
|
125.25% |
|
-206.68% |
|
125.33% |
|
$-0.90 |
|
$-1.56 |
|
$-1.55 |
|